Evidence map›Paper›PMID 28232598›Full record

ArticleThe oncologist2017

Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.

Francesco Panzuto, Elettra Merola, Marianne Ellen Pavel, Anja Rinke, Patrizia Kump, Stefano Partelli, Maria Rinzivillo, Victor Rodriguez-Laval, Ulrich Frank Pape, Rainer Lipp and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. European journal of nuclear medicine and molecular imaging · 2021
    Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Management of Functional Pancreatic Neuroendocrine Neoplasms.Current treatment options in oncology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Francesco PanzutoDepartment of Digestive and Liver Disease, Sapienza University of Rome - Sant'Andrea Hospital, Rome, Italy.
Elettra MerolaDepartment of Digestive and Liver Disease, Sapienza University of Rome - Sant'Andrea Hospital, Rome, Italy.
Marianne Ellen PavelDepartment of Hepatology and Gastroenterology, Charité Campus Mitte and Virchow Clinic, Charité University Medicine, Berlin, Germany.
Anja RinkeDepartment of Gastroenterology, Philipps-University of Marburg, Germany.
Patrizia KumpClinical Division of Gastroenterology, Medical University Graz, Austria.
Stefano PartelliDivision of Pancreatic Surgery, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy.
Maria RinzivilloDepartment of Digestive and Liver Disease, Sapienza University of Rome - Sant'Andrea Hospital, Rome, Italy.
Victor Rodriguez-LavalDepartment of Radiology Charité University, Campus Virchow Klinikum, Berlin, Germany.
Ulrich Frank PapeDepartment of Hepatology and Gastroenterology, Charité Campus Mitte and Virchow Clinic, Charité University Medicine, Berlin, Germany.
Rainer LippClinical Division of Oncology, Medical University Graz, Austria.
Thomas GressDepartment of Gastroenterology, Philipps-University of Marburg, Germany.
Bertram WiedenmannDepartment of Hepatology and Gastroenterology, Charité Campus Mitte and Virchow Clinic, Charité University Medicine, Berlin, Germany.
Massimo FalconiDivision of Pancreatic Surgery, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy.
Gianfranco Delle FaveDepartment of Digestive and Liver Disease, Sapienza University of Rome - Sant'Andrea Hospital, Rome, Italy gianfranco.dellefave@uniroma1.it.
Azienda Ospedaliera Sant'Andrea · ITCharité - Universitätsmedizin Berlin · DEMedical University of Graz · ATPhilipps University of Marburg · DEVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral risk factors predict clinical outcome in gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs); however, the impact of their combination has not been investigated so far. PATIENTS AND

methodsA retrospective analysis of stage IV GEP-NENs was performed. Multivariate analysis for progression of disease (PD) was performed by Cox proportional hazards method to obtain a risk score. Area under the curve obtained by receiver operating characteristic analysis was used to assess the score performance. Progression-free survival analysis was performed by Kaplan-Meier method.

resultsTwo hundred eighty-three stage IV GEP-NENs were evaluated, including 93 grade 1 neuroendocrine tumors (32.9%), 153 grade 2 neuroendocrine tumors (54%), and 37 grade 3 neuroendocrine carcinomas (13.1%). Independent risk factors for PD were Ki67, proportion of metastatic liver involvement, and presence of extra-abdominal metastases. The risk score was calculated as follows: (0.025 × Ki67) + [(0 if no liver metastases or liver involvement <25%) OR (0.405 if liver involvement 25%-50%) OR (0.462 if liver involvement >50%)] + [(0 if no extra-abdominal metastases) OR (0.528 if extra-abdominal metastases present)]. The risk score accuracy to predict PD was superior compared with the G grading system (area under the curve: 0.705 and 0.622, respectively). Three subgroups of patients with low, intermediate, and high risk of PD according to risk score were identified, median progression-free survival being 26 months, 19 months, and 12 months, respectively.

conclusionIn stage IV GEP-NENs, a risk score able to predict PD was obtained by combining Ki67, proportion of metastatic liver involvement, and presence of extra-abdominal metastases. The score may help to discriminate patients with different progression risk level to plan tailored therapeutic approaches and follow-up programs.

Indexed as

Disease ProgressionAgedDisease-Free SurvivalFemaleHumansIntestinal NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingNeuroendocrine TumorsPancreatic NeoplasmsProportional Hazards ModelsRisk FactorsStomach NeoplasmsDisease progressionKi67MetastasesNeuroendocrine tumorsPrognosisRisk score

Identifiers

PMID28232598
PMCPMC5388376
OpenAlexW2589764398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.